Sanofi promis­es mon­ey back for dis­con­tin­ued blood dis­or­der treat­ment – in some cas­es

Months af­ter Pfiz­er launched its sec­ond drug war­ran­ty pro­gram, Sanofi is hop­ping on the trend.

The French phar­ma gi­ant set up a war­ran­ty pro­gram for Ca­blivi, of­fer­ing med­ical in­sti­tu­tions a po­ten­tial re­fund if in­pa­tient treat­ment doesn’t work out. Pa­tients must re­ceive the drug in a hos­pi­tal set­ting in or­der to qual­i­fy, and Sanofi will on­ly cov­er the cost of up to six dos­es for pa­tients who don’t re­spond, or up to 12 dos­es for those who wors­en while on treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.